ATE471335T1 - Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden - Google Patents

Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden

Info

Publication number
ATE471335T1
ATE471335T1 AT03814236T AT03814236T ATE471335T1 AT E471335 T1 ATE471335 T1 AT E471335T1 AT 03814236 T AT03814236 T AT 03814236T AT 03814236 T AT03814236 T AT 03814236T AT E471335 T1 ATE471335 T1 AT E471335T1
Authority
AT
Austria
Prior art keywords
hcmv
human
antigens
codon
optimized
Prior art date
Application number
AT03814236T
Other languages
German (de)
English (en)
Inventor
Gary Hermanson
Andrew Geall
Mary Kopke Wloch
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Application granted granted Critical
Publication of ATE471335T1 publication Critical patent/ATE471335T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C07K14/045—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AT03814236T 2002-12-23 2003-12-19 Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden ATE471335T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43554902P 2002-12-23 2002-12-23
PCT/US2003/040685 WO2004058166A2 (en) 2002-12-23 2003-12-19 Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection

Publications (1)

Publication Number Publication Date
ATE471335T1 true ATE471335T1 (de) 2010-07-15

Family

ID=32682258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03814236T ATE471335T1 (de) 2002-12-23 2003-12-19 Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden

Country Status (12)

Country Link
US (5) US7410795B2 (Direct)
EP (2) EP2311848B1 (Direct)
JP (2) JP2006511221A (Direct)
AT (1) ATE471335T1 (Direct)
AU (1) AU2003301148A1 (Direct)
CA (2) CA2508228C (Direct)
DE (1) DE60333035D1 (Direct)
DK (1) DK2311848T3 (Direct)
ES (1) ES2429338T3 (Direct)
PT (1) PT2311848E (Direct)
SI (1) SI2311848T1 (Direct)
WO (1) WO2004058166A2 (Direct)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105574B1 (en) * 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
DE60012711T2 (de) * 1999-03-26 2005-08-18 Vical, Inc., San Diego Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
US20070105799A1 (en) * 2002-09-10 2007-05-10 Vical Incorporated Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection
AU2003293196A1 (en) * 2002-12-23 2004-07-29 Vical Incorporated Method for producing sterile polynucleotide based medicaments
CA2508279A1 (en) 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
CA2508228C (en) 2002-12-23 2013-12-17 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
EP1607485A1 (en) * 2004-06-14 2005-12-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for quantifying VEGF121 isoform in a biological sample
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
CN1307423C (zh) * 2005-01-08 2007-03-28 王明丽 重组抗原pp65包被酶标反应板的制法及ELISA检测试剂盒
JP2006223194A (ja) * 2005-02-17 2006-08-31 Tosoh Corp スタニオカルシン１（ＳＴＣ１）ｍＲＮＡの測定方法
CN101163714A (zh) * 2005-02-24 2008-04-16 马萨诸塞大学 流感病毒核酸、多肽及其用途
EP1984505B1 (en) * 2006-01-13 2019-12-25 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
US9182398B2 (en) 2006-04-01 2015-11-10 Medical Service Consultation International, Llc Methods and compositions for detecting fungi and mycotoxins
DK2139515T4 (da) * 2007-03-30 2024-03-04 The Research Foundation Of The State Univ Of New York Attenuerede vira, der er nyttige til vacciner
US20090004203A1 (en) * 2007-05-29 2009-01-01 Vical Incorporated Methods of treating measles infectious disease in mammals
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
CN102123732A (zh) 2008-06-20 2011-07-13 杜克大学 用于引发免疫应答的组合物，方法及试剂盒
WO2010014567A2 (en) * 2008-08-01 2010-02-04 Merck & Co., Inc. Variant hcmv pp65, ie1, and ie2 polynucleotides and uses thereof
US20100068718A1 (en) 2008-08-22 2010-03-18 Hooper Dennis G Methods and Compositions for Identifying Yeast
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
JP5833443B2 (ja) * 2009-08-29 2015-12-16 株式会社バイオメッドコア 抗原特異的ｔ細胞誘導能測定法
US8962251B2 (en) 2009-10-08 2015-02-24 Medical Service Consultation International, Llc Methods and compositions for identifying sulfur and iron modifying bacteria
AU2010313339B2 (en) 2009-10-30 2016-05-26 The Administrators Of The Tulane Educational Fund Peptide compositions and methods for inhibiting herpesvirus infection
US20110256535A1 (en) * 2010-02-11 2011-10-20 Intelligent Medical Devices, Inc. Optimized oligonucleotides and methods of using same for the detection, isolation, amplification, quantification, monitoring, screening and sequencing of clostridium difficile genes encoding toxin b, and/or toxin a and/or binary toxin
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
SI2590626T1 (sl) 2010-07-06 2016-01-29 Glaxosmithkline Biologicals S.A. Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA
RS63817B1 (sr) 2010-07-06 2023-01-31 Glaxosmithkline Biologicals Sa Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
WO2012006369A2 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
CN108042799A (zh) 2010-07-06 2018-05-18 诺华股份有限公司 阳离子水包油乳液
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
HUE061068T2 (hu) 2010-08-31 2023-05-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogént kódoló RNS szállítására
US9127321B2 (en) * 2010-10-06 2015-09-08 The Translational Genomics Research Institute Method of detecting Coccidioides species
US20140030292A1 (en) 2010-10-11 2014-01-30 Novartis Ag Antigen delivery platforms
ES3018416T3 (es) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
PL2707385T3 (pl) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Prefuzyjne antygeny RSV F
ME03491B (me) 2011-06-08 2020-01-20 Translate Bio Inc Kompozicije lipidnih nanočestica i postupci za isporuku irnk
WO2013006834A1 (en) 2011-07-06 2013-01-10 Novartis Ag Oil-in-water emulsions that contain nucleic acids
JP2014520807A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー 免疫原性組成物およびその使用
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
TWI570240B (zh) 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
CN104105504A (zh) 2011-10-11 2014-10-15 诺华股份有限公司 重组多顺反子核酸分子
BR112014011229B1 (pt) 2011-11-11 2021-10-13 Variation Biotechnologies, Inc Partículas vírus-like (vlp), composição farmacêutica compreendendo a referida partícula, método de produção e uso da mesma
EP3613431B1 (en) 2012-03-27 2023-01-11 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
EP2869842A1 (en) 2012-07-06 2015-05-13 Novartis AG Immunogenic compositions and uses thereof
WO2014011210A1 (en) 2012-07-11 2014-01-16 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
EP3795694A3 (en) 2012-10-02 2021-06-23 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
HK1214962A1 (zh) 2013-01-10 2016-08-12 Seqirus UK Limited 流感病毒免疫原性组合物及其应用
EP2765137A1 (en) 2013-02-07 2014-08-13 Sanofi Pasteur Induction of cross-reactive cellular response against rhinovirus antigens
ES2797547T3 (es) 2013-03-15 2020-12-02 Applied Food Biotech Inc Receptores del sabor amargo felino y métodos.
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3110401A4 (en) 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US20180289792A1 (en) 2015-10-22 2018-10-11 ModernaTX. Inc. Sexually transmitted disease vaccines
US11643441B1 (en) 2015-10-22 2023-05-09 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (VZV)
EP3364981A4 (en) * 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2018009814A1 (en) 2016-07-08 2018-01-11 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of disorders and diseases involving rdh12
EP3528821A4 (en) * 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
EP3528827A4 (en) 2016-10-21 2020-11-04 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
MA50335A (fr) 2016-12-08 2020-08-19 Modernatx Inc Vaccins à acide nucléique contre des virus respiratoires
EP3582790A4 (en) 2017-02-16 2020-11-25 ModernaTX, Inc. VERY POWERFUL IMMUNOGENIC COMPOSITIONS
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
WO2018213618A1 (en) 2017-05-17 2018-11-22 The General Hospital Corporation Gene therapy for tuberous sclerosis
ES3003260T3 (en) 2017-06-15 2025-03-10 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and uses thereof
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
MX2020007945A (es) 2018-01-29 2020-09-24 Merck Sharp & Dohme Proteinas f del rsv estabilizadas y usos de las mismas.
CN109082413B (zh) * 2018-09-18 2023-01-10 四川安可瑞新材料技术有限公司 抗人IgG单克隆抗体、其杂交瘤细胞株及应用
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
BR112022015313A2 (pt) 2020-02-14 2022-09-27 Merck Sharp & Dohme Llc Vacina de hpv
CN116096430A (zh) 2020-04-27 2023-05-09 衣阿华大学研究基金会 用于治疗囊性纤维化的组合物和方法
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4208195A1 (en) 2020-09-04 2023-07-12 Access to Advanced Health Institute Live-attenuated rna hybrid vaccine technology
WO2022051024A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Genetically-adjuvanted rna vaccines
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
JP2024516575A (ja) 2021-04-16 2024-04-16 ジェネンテック， インコーポレイテッド 最適化されたｔｌｒ７リガンド及びその使用
US20240261439A1 (en) 2021-06-14 2024-08-08 Bridgebio Gene Therapy Research, Inc. Gene therapy for tuberous sclerosis
AU2022327583A1 (en) 2021-08-11 2024-02-22 King's College London Compositions and methods for improved treatment of disorders affecting the central nervous system
WO2023023152A1 (en) 2021-08-19 2023-02-23 Merck Sharp & Dohme Llc Thermostable lipid nanoparticle and methods of use thereof
WO2023228116A1 (en) 2022-05-24 2023-11-30 Access To Advanced Health Institute Intranasal administration of thermostable rna vaccines
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
JP2025534371A (ja) 2022-09-30 2025-10-15 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック Ｏｐａ１遺伝子変異に関連付けられる疾患を治療するためのｏｐａ１プレメッセンジャーｒｎａのトランススプライシングによる療法
WO2024147114A1 (en) 2023-01-06 2024-07-11 Bloomsbury Genetic Therapies Limited Compositions and methods for treating parkinson's disease
KR20260008117A (ko) 2023-05-08 2026-01-15 머크 샤프 앤드 돔 엘엘씨 노로바이러스 vp1 항원을 코딩하는 폴리뉴클레오티드 및 그의 용도
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US6242567B1 (en) 1984-07-27 2001-06-05 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US6133433A (en) 1984-07-27 2000-10-17 City Of Hope Method for detection and prevention of human cytomegalovirus infection
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US6162620A (en) 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US5124440A (en) 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
US5547834A (en) 1988-01-29 1996-08-20 Chiron Corporation Recombinant CMV neutralizing proteins
DE68929478T2 (de) 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5837693A (en) 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5885971A (en) 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US5721354A (en) * 1995-03-31 1998-02-24 Aviron Human cytomegalovirus DNA sequences
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
US6020481A (en) 1996-04-01 2000-02-01 The Perkin-Elmer Corporation Asymmetric benzoxanthene dyes
EP0914441A2 (en) * 1996-04-23 1999-05-12 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
FR2753512B1 (fr) * 1996-09-19 1998-12-31 Sachs Ind Sa Chaine de transmission notamment pour cycle
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6156317A (en) 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
JP4434479B2 (ja) * 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
KR100239879B1 (ko) 1997-11-05 2000-02-01 김상조 간암 예방 및 치료용 생약제
JP3253590B2 (ja) * 1998-08-31 2002-02-04 シャープ株式会社 ハーフトーンマスクの製造方法
DE60012711T2 (de) * 1999-03-26 2005-08-18 Vical, Inc., San Diego Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
FR2804028B1 (fr) 2000-01-21 2004-06-04 Merial Sas Vaccins adn ameliores pour animaux de rente
US6835383B2 (en) * 2000-03-23 2004-12-28 City Of Hope Protein kinase deficient, immunologically active CMVpp65 mutants
EP1278551A2 (en) 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
ATE318908T1 (de) 2000-05-18 2006-03-15 Geneart Gmbh Synthetische gene für gagpol und deren verwendungen
CA2411167A1 (en) * 2000-06-23 2002-01-03 Merck & Co., Inc. Polynucleotide vaccine adjuvants and formulations containing cationic surfactants, and methods of use
US20020110567A1 (en) * 2000-08-10 2002-08-15 Volker Gerdts In utero oral nucleic acid immunization
CA2508228C (en) * 2002-12-23 2013-12-17 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US20050283146A1 (en) 2004-06-17 2005-12-22 Lentz David J Thermally extended spiral cryotip for a cryoablation catheter

Also Published As

Publication number Publication date
JP5129292B2 (ja) 2013-01-30
EP1587816B1 (en) 2010-06-16
US9180162B2 (en) 2015-11-10
HK1152945A1 (en) 2012-03-16
US20130017217A1 (en) 2013-01-17
JP2006511221A (ja) 2006-04-06
US8278093B2 (en) 2012-10-02
WO2004058166A3 (en) 2005-06-16
WO2004058166A2 (en) 2004-07-15
EP2311848B1 (en) 2013-07-03
AU2003301148A1 (en) 2004-07-22
EP1587816A4 (en) 2006-06-07
CA2756797A1 (en) 2004-07-15
US7410795B2 (en) 2008-08-12
US20140186382A1 (en) 2014-07-03
CA2508228C (en) 2013-12-17
SI2311848T1 (sl) 2013-11-29
DK2311848T3 (da) 2013-10-14
US20110177124A1 (en) 2011-07-21
US20040209241A1 (en) 2004-10-21
CA2756797C (en) 2015-05-05
PT2311848E (pt) 2013-10-03
US20080085870A1 (en) 2008-04-10
EP1587816A2 (en) 2005-10-26
JP2010227101A (ja) 2010-10-14
DE60333035D1 (de) 2010-07-29
ES2429338T3 (es) 2013-11-14
CA2508228A1 (en) 2004-07-15
US8673317B2 (en) 2014-03-18
US7888112B2 (en) 2011-02-15
AU2003301148A8 (en) 2004-07-22
EP2311848A1 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
ATE471335T1 (de) Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
ES2224655T3 (es) Vacuna antiviral recombinante de la encefalitis equina venezolana.
Yang et al. Antibodies to Schistosoma japonicum (Asian bloodfluke) paramyosin induced by nucleic acid vaccination
ES2362578T3 (es) Composición que comprende la poliproteína ns3/ns4 y el polipéptido ns5b del vhc, vectores de expresión que incluyen las secuencias nucleicas correspondientes y utilización en terapéutica.
US10227385B2 (en) Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection
DK1002110T3 (da) Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
EE04753B1 (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse hTyr-proteiini valmistamiseks ning vaktsiin
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
RU2003103779A (ru) Экспрессионная система
JP2004502460A5 (Direct)
BR0315327A (pt) Antagonistas de il-15
DK263390A (da) Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression
US20230234992A1 (en) Modified betacoronavirus spike proteins
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
Schneeweiss et al. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII
Mihailova et al. Recombinant virus-like particles as a carrier of B-and T-cell epitopes of hepatitis C virus (HCV)
Feng et al. Immune strategies using single-component LipL32 and multi-component recombinant LipL32-41-OmpL1 vaccines against leptospira
WO2004024067A3 (en) Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
Monso et al. Peptide vaccine candidates against classical swine fever virus: T cell and neutralizing antibody responses of dendrimers displaying E2 and NS2–3 epitopes
EP4271698A1 (en) Stable coronavirus proteins and vaccine compositions thereof
NO20005081L (no) Et polypeptid som omfatter aminosyren fra et N-terminalt kolinbindende protein A trunkat, vaksine avledet derav og anvendelser derav
Qiu et al. Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus
Fang et al. Single immunization with a recombinant multiple-epitope protein induced protection against FMDV type Asia 1 in cattle
Drew et al. A comparison of DNA vaccines expressing the 45W, 18k and 16k host-protective antigens of Taenia ovis in mice and sheep
AU2017236578B2 (en) HCV vaccines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties